The development of ‘pharmaceutical’ liposomes is
currently a growth area. The increasing variety of suggested applications, and encouraging results from early
clinical applications and clinical trials of different
liposomal drugs (TABLE 1), need to be augmented by
simple production processes and a variety of qualitycontrol assays for liposomal formulations (BOX 4).
With these requirements met, we are surely likely to
see more liposomal pharmaceuticals on the market in
the foreseeable future.